MARCYRL

Contact us

SELECT * FROM program_table WHERE category = 'Muscu-skeletal system' AND parent_id IS NULL

Our Products

Anoxicam 20 mg

Generic Name
Tenoxicam

Therapeutic area
Muscu-skeletal system

Dosage Form
Tablets, Rectal suppository

Usage
Indicated for the relief of pain and inflammation in osteoarthritis and rheumatoid arthritis.

Flector EP

Generic Name
Diclofenac epolamine

Therapeutic area
Muscu-skeletal system

Dosage Form
Topical gel

Usage
External treatment of pain, inflammation and swelling.

Flector 50 mg

Generic Name
Diclofenac epolamine

Therapeutic area
Muscu-skeletal system

Dosage Form
Soft gelatin capsules

Usage
Can be used in the symptomatic management of rheumatoid arthritis including juvenile chronic arthritis, osteoarthritis, ankylosing spondylitis, psoriatic arthropathy, low back pain and acute musculoskeletal disorders.

Mark-fast

Generic Name
Chlorozoxazone 250 mg + Ibuprofen 200 mg

Therapeutic area
Muscu-skeletal system

Dosage Form
Hard gelatin capsules

Usage
Muscle relaxant, analgesic and NSAID.

Recoxitro

Recoxitro 60 mg

Generic Name
Etoricoxib

Therapeutic area
Muscu-skeletal system

Dosage Form
Film coated tablets

Usage
Indicated in adults and adolescents 16 years of age and older for the symptomatic relief of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and the pains and signs of inflammation associated with acute gouty arthritis.

Recoxitro 90 mg

Generic Name
Etoricoxib

Therapeutic area
Muscu-skeletal system

Dosage Form
Film coated tablets

Usage
Indicated in adults and adolescents 16 years of age and older for the symptomatic relief of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and the pains and signs of inflammation associated with acute gouty arthritis.

Recoxitro 120 mg

Generic Name
Etoricoxib

Therapeutic area
Muscu-skeletal system

Dosage Form
Film coated tablets

Usage
Indicated in adults and adolescents 16 years of age and older for the symptomatic relief of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and the pains and signs of inflammation associated with acute gouty arthritis.

Rheumaton

Rheumaton 500 mg

Generic Name
Nabumetone

Therapeutic area
Muscu-skeletal system

Dosage Form
Tablets

Usage
Relief signs and symptoms of rheumatoid arthritis / Relief signs and symptoms of osteoarthritis

Rheumaton 750 mg

Generic Name
Nabumetone

Therapeutic area
Muscu-skeletal system

Dosage Form
Tablets

Usage
Relief signs and symptoms of rheumatoid arthritis / Relief signs and symptoms of osteoarthritis

Uricodrop

Uricodrop 120 mg

Generic Name
Febuxostat

Therapeutic area
Muscu-skeletal system

Dosage Form
Film coated tablets

Usage
Indicated for the treatment of chronic hyperuricaemia where urate deposition has already occured

Uricodrop 80 mg

Generic Name
Febuxostat

Therapeutic area
Muscu-skeletal system

Dosage Form
Film coated tablets

Usage
Indicated for the treatment of chronic hyperuricaemia where urate deposition has already occured

Uricodrop 40 mg

Generic Name
Febuxostat

Therapeutic area
Muscu-skeletal system

Dosage Form
Film coated tablets

Usage
Indicated for the chronic management of hyperuricaemia in adult patients with gout who has an adequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable.

How drugs are made?

Pharmaceutical products are made through complex processes involving research, development, manufacturing, and quality control. Here's a simplified overview

1. Research and Development (R&D)

We identify potential drug candidates through research, often targeting specific diseases or conditions. This stage involves testing compounds in laboratories and studies to assess efficacy and safety.

Marcyrl Research and development (R&D) is the key driver in developing and introducing new products to national & international markets improving the population’s overall health and economic situation by reducing hospitalizations and operating costs in the healthcare sector through:

• Pre-clinical research & reaching innovative drug delivery systems.
• Experimental design testing.
• Designing production processes.
• Clinical testing.
• Enhancing & developing new concentrations, dosage forms, and delivery systems.

HF0165OA2940/112024

HF0165OA3115/122024

HDHMF0165OA3309/012025

2. Regulatory Approval:

Ensuring that we comply with local and international regulations & standards. Marcyrl's Regulatory department is responsible for preparing and submitting the necessary documentation for product registration with EDA to obtain the required approvals for labeling & packaging. This includes providing data on the safety, efficacy, and quality of the product and managing any changes to the product’s formulation, manufacturing process, or labeling which needs to be approved by the authorities before they can be implemented.

Our Team serves as a liaison between the company and regulatory authorities, handling communications, submissions, and responses to queries or concerns.

HF0165OA2940/112024

HF0165OA3115/122024

HDHMF0165OA3309/012025

3. Manufacturing:

Once regulatory approval is obtained, the drug moves into manufacturing. This involves large-scale production of the drug following strict quality control measures.

HF0165OA2940/112024

HF0165OA3115/122024

HDHMF0165OA3309/012025

4. Quality Control:

Throughout the manufacturing process, quality control checks ensure that the drug meets strict standards for potency, purity, and stability. These checks continue even after the product is on the market to ensure consistency and safety.

HF0165OA2940/112024

HF0165OA3115/122024

HDHMF0165OA3309/012025

5. Distribution and Marketing:

Once manufactured and approved, pharmaceutical products are distributed to pharmacies, hospitals, and other healthcare providers. We use marketing efforts to promote the products to healthcare professionals and consumers.

HF0165OA2940/112024

HF0165OA3115/122024

HDHMF0165OA3309/012025

Let’s work together

Export Capabilites

Marcyrl Pharmaceutical Industries, an Egyptian pharmaceutical manufacturer, has secured investment from Development Partners International (DPI) and Amethis. They focus on specialty generics, to improve access to critical care drugs across Africa. Marcyrl’s growth includes expanding its product portfolio and addressing the demand for affordable specialty generics in Africa. The investment underscores the significance of the pharmaceutical sector and Marcyrl’s commitment to bridging healthcare gaps in the continent.

Capitalizing on our EU-approved GMP sites, Marcyrl Pharmaceutical Industries is exporting a wide range portfolio of medicines to 23 export markets including GCC, LEVANT, and AFRICA

Our ambitious plan to expand our export business in Africa, CIS, GCC, and LATAM.

Why partner with Marcyrl

A Wide portfolio including a niche
in hormonal and respiratory

325 SKUs mainly in chronic disease areas; 300 SKUs in the pipeline A portfolio spanning 15 TAs, in particular female health/fertility, cardiovascular, urology, neuroscience, gastroenterology, etc. Niche in novel, high-complexity products (in particular hormonal, respiratory)

Why partner with Marcyrl

Wide portfolio including niche
in hormonal and respiratory products

Top-notch R&D and manufacturing capabilities with EU GMP-certified facilities Cost competitiveness built on world-class procurement and lean operations – Track record of effective cost containment despite sharp currency devaluation 2017-2021; Leadership in the tender market (11% of sales in 2021)

Why partner with Marcyrl

Track record of registering and
commercializing in export markets

Existing export footprint
in 23 countries outside of Egypt
107 successful registrations in export markets,
106 products under registration

Why partner with Marcyrl

Strong management team, backed by
leading institutional investors

Experienced management with diverse expertise
Entry of DPI and Amethis in 2023
- combined AUM of USD 3.6 billion,
Africa focused with strong pharma exposure

Facilities

Pharma
Hormones
Inhalers

Collaboration

Why partner with us
How we could work together

Therapeutic areas

Alimintary & Metabolism
Blood & Blood Forming Organs
Cardiovascular
Dermatological
Genital & urinary systems & Sex Hormones
Systemic Hormones
Systemic Anti-infectives
Antineoplastic & Immunomodulators
Muscu-skeletal system
Nervous system
Parasitology
Respiratory
Sensory organs

Head Office

Tel
(202)22678596
(202)22678597

Fax
(202)22660905

info@marcyrl.com

16 El Mosheer Ahmed Ismail St., Square 1160, Sheraton, Cairo, Egypt

Socials

Instagram

Youtube

Linkedin

Scroll